Latest executive order could shake up US pharma industry
Under the scheme, drugmakers discount price of medicines sold in bulk to healthcare system
Pharma group looks to take advantage as Wegovy and Ozempic start to go off patent next year
Anaesthetics are not putting patients to sleep, doctors warn, in call for greater access to foreign medicine
Pharma groups say higher levy will stifle growth of life sciences
Novo Nordisk shares hit as government adds blockbuster weight-loss treatments to new round of negotiations
Federal Trade Commission says companies ‘hiked costs’ for medicines, including cancer and HIV treatments
Funding for existing services would have helped more patients
State-backed insurance programmes would fund drugs for obese patients without separate health conditions
European Commission says company abused ‘dominant position’ to ‘artificially’ extend patent protection of MS medicine Copaxone
Expiry of Novo Nordisk’s UK patent for Saxenda seen as offering a ‘dry run’ for future generic versions of Ozempic
CBO analysis says savings from other health benefits would not offset expense of weight-loss jabs
Senator Bernie Sanders accuses Ozempic and Wegovy maker of ‘ripping off’ Americans
Complaint alleges pharmacy benefit managers owned by CVS, Cigna and UnitedHealth are keeping prices high
US telehealth groups including Hims & Hers and Ro could find new revenue streams under threat
US group races to overcome production bottleneck to meet demand for anti-obesity medicine Zepbound
Easing the squeeze on the share of health spending that goes on medicine may alleviate pain
Spending watchdog declines to give green light to lecanemab for patients in England
Administration claims victory in talks to cut the costs of 10 critical medicines
Drugmakers will receive flat fees for new medicines in push to avoid encouraging overuse
Nice blames cost for not recommending Enhertu, which has helped patients in clinical trials live longer
Swiss drugmaker says it will only sell medication privately if health systems cannot pay
New drug Kisunla will be 20% more than rival as drugmaker claims it requires fewer treatments
Alcohol, food, tobacco and fossil fuel sectors oppose efforts to target conditions linked to 2.7mn deaths a year, warns WHO
People with cystic fibrosis, epilepsy and diabetes among those struggling with medicine shortages
